Health and Fitness Health and Fitness
Mon, November 1, 2010
[ Mon, Nov 01st 2010 ] - Market Wire
NeoStem to Present at Cell Therapy Industry Summi .. eld on November 3-5, 2010 in Carlsbad, California
[ Mon, Nov 01st 2010 ] - Market Wire
Clinical Data, Inc. Granted Orphan Drug Designati .. for PRX-8066 for Pulmonary Arterial Hypertension
[ Mon, Nov 01st 2010 ] - Market Wire
Gileada?s onderzoeksverbindingen GS 9190 en GS 92 .. erking met standaard zorgtherapien bereiken subst
[ Mon, Nov 01st 2010 ] - Market Wire
Inhibitex Initiates Phase 1b Multiple Ascending D .. l of INX-189 in Patients with Chronic Hepatitis C
[ Mon, Nov 01st 2010 ] - Market Wire
American Anesthesiology Announces the Acquisition of Greensboro, NC, Group Practice
[ Mon, Nov 01st 2010 ] - Market Wire
Hepatitis-C-Prfprparate GS 9190 und GS 9256 von G .. Phase II zusammen mit Standardtherapien wesentli
[ Mon, Nov 01st 2010 ] - Market Wire
ARIAD to Webcast Conference Call on Third Quarter 2010 Financial Results
[ Mon, Nov 01st 2010 ] - Market Wire
Orthovita to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Theragenics to Report Third Quarter 2010 Financial Results Tuesday, November 9
[ Mon, Nov 01st 2010 ] - Market Wire
I composti sperimentali per l'epatite C di Gilead .. azione con terapie standard di cura ottengono una
[ Mon, Nov 01st 2010 ] - Market Wire
Two Directors Step Down from Elan Board in Accordance with Previously Announced Intention
[ Mon, Nov 01st 2010 ] - Market Wire
Health Management Associates, Inc. to Present at the Oppenheimer 21st Annual Healthcare Conference
[ Mon, Nov 01st 2010 ] - Market Wire
Porex Corporation Divests Surgical Division to Stryker Corporation
[ Mon, Nov 01st 2010 ] - Market Wire
Medisafe 1 Technologies Appoints Tali Skoczylas as Chair of Medical Advisory Board
Sat, October 30, 2010
[ Sat, Oct 30th 2010 ] - Market Wire
A Celgene anuncia resultados financeiros e operacionais recordes no terceiro trimestre de 2010
[ Sat, Oct 30th 2010 ] - Market Wire
Viread® for Hepatitis B Maintains Antiviral Supp .. ent of Resistance Through Four Years of Treatment
[ Sat, Oct 30th 2010 ] - Market Wire
New Data From Phase 3 Studies Showed Superior SVR .. with Telaprevir-Based Combination Therapy in Peop
[ Sat, Oct 30th 2010 ] - Market Wire
Salix Pharmaceuticals Previews Data Slated for Pr .. ting of the American Association for the Study of
[ Sat, Oct 30th 2010 ] - Market Wire
Gileada?s Investigational Hepatitis C Compounds G .. tion with Standard of Care Therapies Achieve Subs
Fri, October 29, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Announces a Stron .. eement with Majority of Senior Subordinated Noteh
[ Fri, Oct 29th 2010 ] - Market Wire
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
[ Fri, Oct 29th 2010 ] - Market Wire
Forest Announces FDA Approval of Teflaroa" (cefta .. ment of Community-Acquired Bacterial Pneumonia an
[ Fri, Oct 29th 2010 ] - Market Wire
FDA Classifies Previous Field Action of Medtronic Surgical Device as Class I Recall
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Present at Two Upcoming Investor Conferences
[ Fri, Oct 29th 2010 ] - Market Wire
ArthroCare Announces Third Quarter 2010 Financial Results Press Release and Conference Call Dates
[ Fri, Oct 29th 2010 ] - Market Wire
Wright Medical Group, Inc. to Participate in the 2010 Annual Credit Suisse Healthcare Conference
[ Fri, Oct 29th 2010 ] - Market Wire
Inhibitex to Host Conference Call to Report Third Quarter Financial Results on November 9, 2010
[ Fri, Oct 29th 2010 ] - Market Wire
Fitch Affirms Boston Scientific's IDR at 'BB+'; Outlook to Positive
[ Fri, Oct 29th 2010 ] - Market Wire
Ligand to Report Third Quarter Results on November 9
[ Fri, Oct 29th 2010 ] - Market Wire
Teva Invites Public to Listen to Its Respiratory Opportunity Meeting Webcast

Teva Invites Public to Listen to Its Respiratory Opportunity Meeting Webcast


Published on 2010-10-29 10:11:38 - Market Wire
  Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast of its Respiratory Opportunity Meeting on Thursday, November 4, 2010 at 10:00 a.m. ET.

What:

Tevaa™s Respiratory Opportunity Meeting

Who:

Teva Management

When:

Thursday, November 4, 2010 at 10:00 a.m. ET

Where:

[ www.tevapharm.com/financial/ ] or [ http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=73925&eventID=3437263 ]

How:

Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.

Contributing Sources